Julie Grabow, an oncologist at the Fred Hutchinson Cancer Center in Seattle, recently prescribed an exciting new therapy for a 60-year-old woman with metastatic breast cancer — Afinitor made by Novartis. There was a catch, though. Novartis is charging $10,000 per month for the drug
With reference pricing, to charge Medicare extra companies get three years to show that a new, costly treatment is better than the old one.
FDA shouldn’t cave to pressure and allow Genentech to keep advanced metastatic breast cancer on the Avastin label, argues Merrill Goozner.
Clinical trials that compare effectiveness–and safety–of new drugs with old drugs would not only save lives, but money as well, says Merrill Goozner